Product Information
LAMIVUDINE HBV 100 MG TABLET is a generic product labeled by Apotex Corp., priced at $9.4765 per EA under NDC 60505325006. Its NADAC has been published 621 times since Apr 23, 2014.
FDA first approved this application on Jan 2, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Apotex Corp.NDC
60505325006
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMIVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA202941FDA Approved
1/2/2014
TE Code
AB
On Market Since
1/3/2014
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE HBV 100 MG TABLET has been published 621 times since Apr 23, 2014, and over the history we have for it it has declined 11.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.4765 per EA |
|---|---|
| All-time high | $11.2082 (Nov 12, 2014) |
| All-time low | $1.5548 (May 17, 2023) |
| 52-week high | $10.0366 |
| 52-week low | $8.6264 |
| Median price | $4.5803 |
| Average price | $5.4470 |
| Largest weekly change | +160.1% (Sep 18, 2024) |
| Weeks tracked | 621 |
| Tracking since | Apr 23, 2014 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 14% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Apotex Corp. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamivudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE HBV 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE HBV 100 MG TABLET, manufactured by Apotex Corp., is $9.4765 per EA (NDC 60505325006), effective Sep 30, 2026.
How has the price of LAMIVUDINE HBV 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE HBV 100 MG TABLET has declined 11.6%. It has been tracked across 621 weekly CMS publications since Apr 23, 2014.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE HBV 100 MG TABLET?
Since Apr 23, 2014, the NADAC for LAMIVUDINE HBV 100 MG TABLET has ranged from a low of $1.5548 (May 17, 2023) to a high of $11.2082 (Nov 12, 2014), with a median of $4.5803 per EA.
Are there cheaper alternatives to LAMIVUDINE HBV 100 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMIVUDINE HBV 100 MG TABLET, is $8.1597 per EA — about 14% below LAMIVUDINE HBV 100 MG TABLET.
Who manufactures LAMIVUDINE HBV 100 MG TABLET?
LAMIVUDINE HBV 100 MG TABLET (NDC 60505325006) is labeled by Apotex Corp., and CMS classifies it as a generic product.